AUTHORS
Yumeng Zhang, MD, Brandon Cardon, MD2, Jongphil Kim, PhD3, Richard Corona4, Shannen Whiddon5, Janice Bennett6, Anthony Suda, NP7, Christopher Ryder, MD PhD8, Bijal Shah, MD, MS9, Supreet Kaur, MD10, Celeste Bello, MD11, Leidy Isenalumhe, MD, MS12, Sameh Gaballa, MD13, Nicholas Figura, MD14, Javier Pinilla-Ibarz, MD PhD15, L. Frank Glass16, Lubomir Sokol, MD, PhD17
AFFILIATIONS
1 Moffitt Cancer Center, Tampa, Florida, United States
2 University of South Florida, Tampa, Florida, United States
3 Moffitt Cancer Center, Tampa, Florida, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 Moffitt Cancer Center, Tampa, Florida, United States
7 Moffitt Cancer Center, Tampa, Florida, United States
8 Moffitt Cancer Center, Tampa, Florida, United States
9 Moffitt Cancer Center, Tampa, Florida, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 Moffitt Cancer Center, Tampa, Florida, United States
13 Moffitt Cancer Center, Tampa, Florida, United States
14 Moffitt Cancer Center, Tampa, Florida, United States
15 Moffitt Cancer Center, Tampa, Florida, United States
16 University of South Florida, Tampa, Florida, United States
17 Moffitt Cancer Center, Tampa, Florida, United States
ABSTRACT
Introduction
Cutaneous T-cell lymphoma (CTCL) is a rare, incurable lymphoma; patients progressing after skin-directed therapy, phototherapy, extracorporeal photopheresis (ECP), or total skin electron beam therapy (TSEBT) often require systemic therapy. Interferon alfa is active in CTCL, but short-acting forms require frequent injection and cause dose-related toxicity. Ropeginterferon alfa-2b is a monopegylated, long-acting interferon approved for polycythemia vera; its prolonged pharmacokinetics permit less frequent dosing. We report the first US prospective trial of ropeginterferon alfa-2b in CTCL.
Methods
MCC 23455 (NCT07047885) is a single-center, investigator-initiated phase I/Ib study using a Bayesian Optimal Interval (BOIN) design to identify the recommended phase 2 dose (RP2D). Eligible patients had relapsed/refractory CTCL (mycosis fungoides [MF], Sezary syndrome [SS], lymphomatoid papulosis [LyP], or other variants), stage IA-IIIB at screening, with prior failure of skin-directed therapy or less-than-complete response to phototherapy, ECP, or TSEBT; stable schedule of concurrent phototherapy/ECP was permitted. Ropeginterferon alfa-2b was initiated at 100, 150, or 250 mcg subcutaneously every 2 weeks and escalated every 2 weeks to assigned target doses of 250, 350, or 500 mcg, respectively, reached by week 5. The primary endpoint was dose-limiting toxicity (DLT; grade >=3 nonhematologic or grade >=4 hematologic toxicity within 6 weeks) and RP2D; secondary endpoints included objective response rate (ORR) by ISCL/EORTC/USCLC 2022 global criteria and AEs (CTCAE v5.0). Under the BOIN design, additional patients are being enrolled at 250 and 350 mcg to characterize cumulative tolerability and inform RP2D selection.
Results
As of July 1, 2026, 9 patients had received >=1 dose and comprised the safety population; all completed the 6-week DLT window and >=1 post-baseline assessment and were DLT- and response-evaluable. Median age was 67 (range 18-82); 5 male; 6 White, 2 Black, 1 multiracial. Eight had MF/SS (MF n=5, folliculotropic MF n=2, SS n=1) and 1 had LyP (refractory to multiple systemic therapies); 3 had large cell transformation. Among the 8 MF/SS patients, stage at screening was IA (n=2) and IB (n=6); the SS patient was T2N0M0B0 after mogamulizumab-induced blood clearance. Median baseline modified Severity Weighted Assessment Tool (mSWAT) score was 16 (range 1.5-66); median prior systemic therapies 2 (range 0-4); 3 had prior TSEBT. Two patients intolerant of prior peginterferon alfa-2a for cytopenia remained on ropeginterferon alfa-2b without recurrent grade >=2 cytopenia. Patients were treated at 250, 350, and 500 mcg (n=3 each); no DLTs occurred. Grade 2 treatment-related AEs occurred in 2/3, 1/3, and 3/3 patients at 250, 350, and 500 mcg; one grade 3 neutropenia and both dose reductions occurred at 500 mcg. The most common treatment-related AEs were fatigue (n=5), musculoskeletal symptoms (n=3), and flu-like symptoms (n=2). One patient (82 yo, F) at 350 mcg developed treatment-related grade 2 pneumonitis at week 9, requiring hospitalization without oxygen; it resolved with oral corticosteroids and Ropeginterferon alfa-2b was discontinued. Among 8 MF/SS patients, global ORR was 5/8 (1 complete response [CR], 4 partial responses [PR]); the LyP patient achieved a PR by prespecified mSWAT skin criteria. Responses occurred at all dose levels: 3/3 at 250, 1/3 at 350, and 2/3 at 500 mcg. Median best mSWAT reduction among responders was 74% (range 50-100%). Both patients with B1b blood involvement cleared to B0. Median time to response was 15 weeks (range 6-26). Stable schedule of phototherapy/ECP was continued in 7/9 patients; responses occurred in 5/7 with concurrent therapy and 1/2 without. At a median follow-up of 23 weeks, 7/9 remained on treatment, and 5/6 responses were ongoing.
Conclusion
In this ongoing phase I/Ib study, no protocol-defined DLTs occurred across ropeginterferon alfa-2b target doses of 250-500 mcg. One grade 3 neutropenia and one grade 2 pneumonitis (leading to discontinuation) occurred, with a higher rate of toxicity and dose modification among patients receiving 500mcg. Responses were observed at all dose levels, with an MF/SS ORR of 5/8 (1 CR) and a median time to response of 15 weeks. Under the BOIN design, accrual continues at 250 and 350 mcg to characterize cumulative tolerability and efficacy to inform RP2D selection.
DISCLOSURES
Yumeng Zhang, MD: Curio Science - Honoraria; Plexus Communications - Honoraria; Acrotech Biopharma - Consultancy (Includes expert testimony); Citius Oncology - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Arima Genomics - Consultancy (Includes expert testimony); Kyowa Hakko Kirin Pharma, Inc. - Consultancy (Includes expert testimony); AbbVie, Inc. - Consultancy (Includes expert testimony)